HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RIBOLIFE-B

58.800

-2.200-3.61%

Volume:272.20K

Turnover:15.44M

Market Cap:10.03B

PE:-31.70

High:59.800

Open:59.000

Low:54.000

Close:61.000

52wk High:95.800

52wk Low:54.000

Shares:170.55M

HK Float Shares:170.55M

Volume Ratio:1.14

T/O Rate:0.16%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.855

ROE:--

ROA:--

PB:-151.26

PE(LYR):-31.70

PS:49.06

Loading ...

Overview Company News Filings

Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial

MT Newswires Live

Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China

Bulletin Express

RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia

Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China

THOMSON REUTERS

Suzhou Ribo to start China Phase III trial of RBD7022 for hyperlipidemia

GTHT: Factor XI Drives New Era in Anticoagulant Therapy with Multi-Technological Approaches

China International Capital Initiates Coverage on RIBOLIFE-B (06938) with "Outperform" Rating, Sets HK$100 Target Price

Suzhou Ribo's Swedish Clinical Team Likely Sets It Apart From Peers -- Market Talk

Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness

Simply Wall St.

RIBOLIFE-B (06938) Issues 4.7414 Million H Shares Following Full Exercise of Over-Allotment Option

Suzhou Ribo (06938) Increases Issued H Shares Following Over-Allotment Option Exercise

Bulletin Express

SASAC Urges Central Enterprises to Boost Computing Power Investment; SanDisk Shares Surge Over 10%

Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash

THOMSON REUTERS

Suzhou Ribo (6938) and Madrigal Sign Exclusive Worldwide Licensing Deal for Pre-Clinical siRNA Assets

Bulletin Express

Madrigal, Suzhou Ribo in license deal for liver‑disease programs

RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets

BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal

Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science

Suzhou Ribo Life Science - to Receive $60 Mln Upfront Payment, up to $4.4 Bln Total

THOMSON REUTERS

Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/06938/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"RIBOLIFE-B","latestPrice":58.8,"timestamp":1772611695096,"preClose":61,"halted":0,"volume":272200,"delay":0,"changeRate":-0.03606557377049185,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"Not Yet Opened","change":-2.2,"latestTime":"03-04 16:08:15","open":59,"high":59.8,"low":54,"amount":15435300,"amplitude":0.095082,"askPrice":58.8,"askSize":5400,"bidPrice":57.5,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772674200000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":61,"openAndCloseTimeList":[[1772587800000,1772596800000],[1772600400000,1772611200000]],"volumeRatio":1.141491,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-1.855,"volumeRatio":1.141491,"shares":170554910,"dividePrice":0,"high":59.8,"amplitude":0.095082,"preClose":61,"low":54,"week52Low":54,"pbRate":"-151.26","psRate":"49.06","week52High":95.8,"institutionHeld":0,"latestPrice":58.8,"committee":-0.636364,"eps":-1.855,"divideRate":0,"volume":272200,"delay":0,"ttmEps":-1.502,"open":59,"prevYearClose":57.97,"prevWeekClose":68.5,"prevMonthClose":68.5,"prevQuarterClose":57.97,"fiveDayClose":71.5,"twentyDayClose":68.8,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-03-03","current":-37.882823,"percent":1,"low":-50.513246,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"high":-41.67233,"avg":-47.34064,"sd":2.663177,"marketCap":10403849510},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445},{"date":"2026-02-20","current":-49.493094,"twenty":-49.901155,"median":-49.02522,"eighty":-48.248265,"marketCap":12356703229},{"date":"2026-02-27","current":-46.28708,"twenty":-49.778496,"median":-48.557346,"eighty":-47.185619,"marketCap":11683011335},{"date":"2026-03-03","current":-41.67233,"twenty":-49.493094,"median":-48.535001,"eighty":-45.408639,"marketCap":10403849510}],"updateTime":1772601887232},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2616016068","title":"Suzhou Ribo Life Science's Cholesterol Medicine to Begin Phase 3 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2616016068","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616016068?lang=en_us&edition=fundamental","pubTime":"2026-03-02 11:56","pubTimestamp":1772423773,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science  said a phase 3 clinical of RBD7022 is about to begin after the drug's collaborator, Qilu Pharmaceutical, completed public registration, according to a Hong Kong bourse filing Monday.The drug will be studied as a treatment for high cholesterol to reduce the risk of heart disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1108221887","title":"Suzhou Ribo Life Science (6938) Announces Phase III Clinical Trial Launch for RBD7022 Injection in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1108221887","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108221887?lang=en_us&edition=fundamental","pubTime":"2026-03-02 09:22","pubTimestamp":1772414532,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (6938) announced that RBD7022 Injection, independently developed by the Group, will begin a Phase III clinical trial after completing public registration by...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1132294830","title":"RIBOLIFE-B (06938) to Commence Phase III Trial in China for RBD7022 Injection Targeting Hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=1132294830","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132294830?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:18","pubTimestamp":1772410695,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that its self-developed RBD7022 injection has completed Phase III clinical trial registration by its partner Qilu Pharmaceutical Co., Ltd. The Phase III clinical trial is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK4134","BK1161","III"],"gpt_icon":0},{"id":"2616258877","title":"Suzhou Ribo Life Science Co - Phase Iii Clinical Trial of Rbd7022 Injection for Treatment of Hyperlipidemia to Be Initiated in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2616258877","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616258877?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:09","pubTimestamp":1772410146,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nFWN3ZO04B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2616408877","title":"Suzhou Ribo to start China Phase III trial of RBD7022 for hyperlipidemia","url":"https://stock-news.laohu8.com/highlight/detail?id=2616408877","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616408877?lang=en_us&edition=fundamental","pubTime":"2026-03-02 08:08","pubTimestamp":1772410127,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co. Ltd. said its collaborator Qilu Pharmaceutical has completed public registration in China for a Phase III clinical trial of RBD7022 Injection, an siRNA drug targeting PCSK9 for the treatment of hyperlipidemia, and the study is expected to be initiated. The company did not report clinical results in the announcement, and no timing for presenting trial results was provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Ribo Life Science Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on March 02, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3dWPtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1188158344","title":"GTHT: Factor XI Drives New Era in Anticoagulant Therapy with Multi-Technological Approaches","url":"https://stock-news.laohu8.com/highlight/detail?id=1188158344","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188158344?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:58","pubTimestamp":1771999118,"startTime":"0","endTime":"0","summary":"Demographic aging and rising prevalence of cardiovascular diseases are driving continuous expansion in the antithrombotic drug market. Anticoagulants, as a core category, are experiencing steady...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0201","BK0012","01276","LU0359201612.USD","BK0276","BK0188","BK1564","LU0359202008.SGD","LU1023057109.AUD","BK1147","BK1191","BK1161","LU2543165471.USD","BK0184","601211","BK0028","LU0359201885.HKD","06938","02611","BK0183"],"gpt_icon":0},{"id":"1160415519","title":"China International Capital Initiates Coverage on RIBOLIFE-B (06938) with \"Outperform\" Rating, Sets HK$100 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1160415519","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160415519?lang=en_us&edition=fundamental","pubTime":"2026-02-20 10:10","pubTimestamp":1771553430,"startTime":"0","endTime":"0","summary":"China International Capital issued a research report initiating coverage on RIBOLIFE-B (06938) with an \"Outperform\" rating. Based on a DCF valuation, the firm set a target price of HK$100.0, implying...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2612147185","title":"Suzhou Ribo's Swedish Clinical Team Likely Sets It Apart From Peers -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2612147185","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612147185?lang=en_us&edition=fundamental","pubTime":"2026-02-19 12:32","pubTimestamp":1771475520,"startTime":"0","endTime":"0","summary":"0432 GMT - Suzhou Ribo Life Science's Swedish clinical team appears key to differentiating it from its Chinese pharmaceutical peers, say Macquarie Capital analysts in a note. The company's team in Sweden conducts proof-of-concept trials, which gives these trials global relevance and its clinical data credibility, they say. Ribo also has a broad drug pipeline and partnerships with global pharmaceutical corporates such as Boehringer Ingelheim and Madrigal, which validates the Chinese company's research and development know-how. The pharmaceutical company's sales could grow to CNY13 billion in 2040 from CNY176 million in 2025, they add. Macquarie Capital starts coverage of Ribo with an outperform rating and HK$97.30 target price. Shares last closed 1.5% higher at HK$71.10.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TISI","06938","BK4120","BK1161"],"gpt_icon":0},{"id":"2611200811","title":"Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2611200811","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611200811?lang=en_us&edition=fundamental","pubTime":"2026-02-16 00:29","pubTimestamp":1771172947,"startTime":"0","endTime":"0","summary":"Why Suzhou Ribo Life Science Is Drawing Investor Attention\nSuzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline.\nSee our latest analysis for Suzhou Ribo Life Science.\nThe latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6938/suzhou-ribo-life-science-shares/news/suzhou-ribo-life-science-sehk6938-valuation-check-after-rece","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1159287871","title":"RIBOLIFE-B (06938) Issues 4.7414 Million H Shares Following Full Exercise of Over-Allotment Option","url":"https://stock-news.laohu8.com/highlight/detail?id=1159287871","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159287871?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:17","pubTimestamp":1770877042,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on February 10, 2026, the company issued and allotted 4.7414 million H shares as a result of the full exercise of the over-allotment option.","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"1141269694","title":"Suzhou Ribo (06938) Increases Issued H Shares Following Over-Allotment Option Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=1141269694","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141269694?lang=en_us&edition=fundamental","pubTime":"2026-02-12 14:01","pubTimestamp":1770876090,"startTime":"0","endTime":"0","summary":"According to the latest disclosure dated 12 February 2026, Suzhou Ribo Life Science Co., Ltd. (stock code: 06938) reported a share issuance resulting from the full exercise of an over-allotment...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"1112861737","title":"SASAC Urges Central Enterprises to Boost Computing Power Investment; SanDisk Shares Surge Over 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112861737","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112861737?lang=en_us&edition=fundamental","pubTime":"2026-02-12 08:09","pubTimestamp":1770854983,"startTime":"0","endTime":"0","summary":"The State Council has issued the \"Implementation Opinions on Improving the National Unified Electricity Market System,\" setting targets to establish a basic framework by 2030 and fully complete the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","LU0278937759.USD","06938","09899","VT","BK4585","BK4588","IE0009570106.USD","LU0231459107.USD","SNDK","BK1161","BK1615","BK4170","BK1128"],"gpt_icon":0},{"id":"2610493993","title":"Ribo and Ribocure Announce Exclusive Global Licensing Agreement With Madrigal for Novel Sirna Therapeutics Targeting Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2610493993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610493993?lang=en_us&edition=fundamental","pubTime":"2026-02-11 19:25","pubTimestamp":1770809124,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nTUA5TLHS1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06938","BK4139","MDGL","BK4588","BK4585","BK1161"],"gpt_icon":0},{"id":"1111063693","title":"Suzhou Ribo (6938) and Madrigal Sign Exclusive Worldwide Licensing Deal for Pre-Clinical siRNA Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1111063693","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111063693?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:20","pubTimestamp":1770805243,"startTime":"0","endTime":"0","summary":"Suzhou Ribo Life Science Co., Ltd. (6938) and its subsidiary Ribocure Pharmaceuticals AB reached an exclusive worldwide licensing agreement on February 11, 2026, with Madrigal Pharmaceuticals, Inc....","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938"],"gpt_icon":0},{"id":"2610933985","title":"Madrigal, Suzhou Ribo in license deal for liver‑disease programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933985","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933985?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:10","pubTimestamp":1770804632,"startTime":"0","endTime":"0","summary":"Madrigal, Suzhou Ribo in license deal for liverdisease programsFeb 11  - Madrigal Pharmaceuticals MDGL.O said on Wednesday it has signed an exclusive global license agreement with China-based Suzhou Ribo Life Science 6938.HK and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA programs to treat a type of liver disease.   ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","MDGL","BK1161","BK4588","06938","BK4139"],"gpt_icon":0},{"id":"1132391081","title":"RIBOLIFE-B Enters Exclusive Global Licensing Agreement with Madrigal for siRNA Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=1132391081","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132391081?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:09","pubTimestamp":1770804560,"startTime":"0","endTime":"0","summary":"RIBOLIFE-B (06938) announced that on February 11, 2026 (after trading hours), the company and its subsidiary Ribocure Pharmaceuticals AB entered into an exclusive global licensing agreement with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610933517","title":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal","url":"https://stock-news.laohu8.com/highlight/detail?id=2610933517","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610933517?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:09","pubTimestamp":1770804556,"startTime":"0","endTime":"0","summary":"BRIEF-Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With MadrigalFeb 11 (Reuters) - Suzhou Ribo Life Science Co Ltd 6938.HK:EXCLUSIVE WORLDWIDE LICENSING AGREEMENT WITH MADRIGAL FO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06938","BK4588","BK4585","MDGL","BK1161"],"gpt_icon":0},{"id":"2610333309","title":"Madrigal Pharmaceuticals Licenses Six siRNA Programs from Ribo Life Science","url":"https://stock-news.laohu8.com/highlight/detail?id=2610333309","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610333309?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:03","pubTimestamp":1770804218,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals Inc. has entered into an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA  programs. This partnership will expand Madrigal’s pipeline for metabolic dysfunction-associated steatohepatitis  by advancing next-generation siRNA therapies that target genes implicated in the disease. The collaboration aims to develop precision gene-silencing treatments to address unmet needs in MASH, complementing Madrigal’s foundational therapy, Rezdiffra.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief on February 11, 2026, and i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbLh597:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1161","MDGL","06938","BK4139","BK4585"],"gpt_icon":0},{"id":"2610393801","title":"Suzhou Ribo Life Science - to Receive $60 Mln Upfront Payment, up to $4.4 Bln Total","url":"https://stock-news.laohu8.com/highlight/detail?id=2610393801","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610393801?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06938"],"gpt_icon":0},{"id":"2610338509","title":"Suzhou Ribo Life Science - Licensing Deal for 6 Pre-Clinical Sirna Programs for Treatment of Metabolic Dysfunction-Associated Steatohepatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2610338509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610338509?lang=en_us&edition=fundamental","pubTime":"2026-02-11 18:00","pubTimestamp":1770804041,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z70MV:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MDGL","BK1161","BK4139","06938","BK4588","BK4585"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":44,"code":"91000000","status":"200"}]}}